Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents Big Molecule WatchOn March 20, 2026, Accord BioPharma, Inc.RegulatoryImmunology & InflammationRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) Big Molecule Watch On March 20, 2026, Accord BioPharma, Inc. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Otsuka picks up PTSD drug with $700M Transcend buyNext: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
